Ph2 Study of Fruquintinib plus FOLFIRI as 2L Treatment for mCRC

Phase II Clinical Trial

A Phase II Study Investigating Fruquintinib plus FOLFIRI as Second-Line Treatment for Participants with Metastatic Colorectal Cancer (mCRC)

Indication: Colon Cancer, Rectal Cancer
Trial Number: 07011576
Trial Status: OPEN

Learn more about this clinical trial.

Participating Locations